Publications

Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R et al..  2013.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.. Neoplasia . (1):1-10.

Lin PC, Giannopoulou EG, Park K, Mosquera JM, Sboner A, Tewari AK, Garraway LA, Beltran H, Rubin MA, Elemento O.  2013.  Epigenomic alterations in localized and advanced prostate cancer.. Neoplasia. 15(4):373-83.

Beltran H, Yelensky R, Frampton GM, Park K, , MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM et al..  2013.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.. Eur Urol. 63(5):920-6.

Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, Rubin MA, Nanus DM.  2012.  Challenges in recognizing treatment-related neuroendocrine prostate cancer.. J Clin Oncol. 30(36):386-9.

Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al..  2011.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.. Cancer Discovery. 1(6):487-95.